US · Healthcare · Biotechnology
EPS came in at -1.09 against a street estimate of -0.74 — a miss of 47.3%.
Analysts rate Kailera Therapeutics, Inc. Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $42.40.
| Fund | Stake |
|---|---|
| Bain Capital Investors LLC | 20.25% |
| Bain Capital Life Sciences Investors, LLC | 17.42% |
| RTW INVESTMENTS, LLC | 8.31% |
| Canada Pension Plan Investment Board | 5.63% |
| Atlas Venture Life Science Advisors, LLC | 3.99% |
| FMR Inc | 3.06% |
| BlackRock Inc | 3.03% |
| T. Rowe Price Associates, Inc. | 2.73% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 KAILERA THERAPEUTICS, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and Marketable Securities (as of June 30, 2026): $1.17 billio | 2026-08-12 |
| Results announced · Q3 2026 KAILERA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $1,171.8 million as of June 30, | 2026-08-12 |
| Quarterly report · Q1 2026 KAILERA THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash & Securities Position (March 31, 2026): $111.8 million cash + $407.3 mil | 2026-05-26 |
| Results announced · Q2 2026 KAILERA THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss Q1 2026: $78.9 million (vs. $18.0 million Q1 2025) • R&D expenses | 2026-05-26 |
| Charter / bylaws change · Q2 2026 KAILERA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company completed initial public offering (IPO) on April 20, 2026 • Offered 44,921,875 s | 2026-04-20 |
Readable in the app.
| Announcement | Date |
|---|---|
| IND approval obtained, Phase 3 obesity trials planned for H1 2027 Kailera Therapeutics, a clinical-stage biotech company, reported progress on its obesity drug pipeline in Q2 2026. Key developments include: (1) FDA approval of an Investigational New Drug ( | 2026-08-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kailera Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.